Related Experiment Video

Updated: Aug 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Current status and problems of anticancer drug-induced lung injuries]

Shoji Kudoh1, Akinobu Yoshimura

  • 1Fourth Dept. of Internal Medicine, Nippon Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 13, 2006
PubMed

Insights

Large-scale studies on gefitinib-induced lung injury reveal challenges in anticancer drug development and highlight the need for better surveillance and mechanistic understanding of these severe adverse events.

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Anticancer drug-induced lung injuries (ADILI) pose significant clinical challenges.
  • Gefitinib, an EGFR inhibitor, is associated with notable pulmonary toxicity.
  • Understanding ADILI is crucial for safe and effective cancer therapy.

Purpose of the Study:

  • To analyze clinical investigations of gefitinib-induced lung injury.
  • To identify patterns, risk factors, and diagnostic challenges in ADILI.
  • To underscore issues in new anticancer drug development and post-marketing surveillance.

Main Methods:

  • Review of large-scale clinical investigations on gefitinib.
  • Analysis of clinical features, ethnic variations, and risk factors.
  • Evaluation of diagnostic difficulties and post-marketing surveillance data.

Main Results:

  • Gefitinib-induced lung injury presents diverse clinical features and ethnic differences.
  • Risk factors and diagnostic challenges in ADILI were identified.
  • Underlying problems in anticancer drug development processes were highlighted.

Conclusions:

  • Gefitinib-induced lung injury underscores critical issues in anticancer drug development.
  • Enhanced post-marketing surveillance is essential for managing ADILI.
  • Elucidating the mechanisms of ADILI is vital for effective clinical management.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: